Theravance, Inc. (NASDAQ:THRX)

zzlangerhans (99.75) Submitted: 8/18/2011 1:26:17 PM : Start Price: $17.70 THRX Score: +56.99

When I pooh poohed Theravance almost a year ago, televancin was the lead story and it wasn't a pretty one. Televancin sales and royalties for skin infections were dismal. Meanwhile the FDA had rejected televancin for pneumonia and the company didn't appear motivated to press the issue. At that time, Relovair seemed like a back story with a plot denouement that wouldn't take place until after a major broad market correction.

I seem to have been generally correct, but just barely. My market correction took longer than I anticipated, almost enough time for Relovair to launch out of the box. Enrollment is complete in the registrational trials of Relovair for asthma and for COPD, although topline data isn't anticipated until 2012. Meanwhile follow-on bronchodilators GSK73719 and GSK961081 continue enrollment in late stage trials. With every passing month Theravance looks more and more like the future pulmonary subdivision of GSK. Televancin royalties haven't improved, but in May it received a positive opinion for nosocomial pneumonia from CHMP. That means near certain EU approval for pneumonia within a few months.

You might be protesting that the markets haven't experienced a "correction" yet. I'd say they've corrected enough for me to take accuracy on my red thumb. There's a strong possibility they will correct more and put my new green thumb in a 20 point hole, at which point it is very likely that Theravance will go on the GBMB watchlist for the inevitable recovery.

withoutlimits (80.44) Submitted: 9/30/2010 7:50:58 PM : Start Price: $20.17 THRX Score: -32.92

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

jsgant13 (99.11) Submitted: 9/13/2010 1:06:44 PM : Start Price: $15.11 THRX Score: +88.83

Klarman

Brian7992 (50.37) Submitted: 8/20/2009 7:40:30 AM : Start Price: $15.66 THRX Score: +61.67

Best Bio Bets

jmacn22 (85.86) Submitted: 2/5/2009 12:42:52 PM : Start Price: $16.26 THRX Score: -20.67

Should underperform

gklein711 (55.12) Submitted: 1/8/2008 1:53:53 PM : Start Price: $21.48 THRX Score: +44.47

Therevance appears to be a good company, but hit a rough spot. Should rebound from here.